0HD2 Stock Overview A biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Alnylam Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Alnylam Pharmaceuticals Historical stock prices Current Share Price US$244.60 52 Week High US$303.89 52 Week Low US$142.05 Beta 0.32 1 Month Change -0.61% 3 Month Change -10.68% 1 Year Change 28.19% 3 Year Change 23.33% 5 Year Change 101.60% Change since IPO 82.00%
Recent News & Updates
CEO & Director recently sold US$1.3m worth of stock Nov 30
Alnylam Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Nov 25
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024 Nov 01
Third quarter 2024 earnings released: US$0.87 loss per share (vs US$1.18 profit in 3Q 2023) Nov 01
Alnylam Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 17
Alnylam Pharmaceuticals, Inc. Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Oct 16 See more updates
CEO & Director recently sold US$1.3m worth of stock Nov 30
Alnylam Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Nov 25
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024 Nov 01
Third quarter 2024 earnings released: US$0.87 loss per share (vs US$1.18 profit in 3Q 2023) Nov 01
Alnylam Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 17
Alnylam Pharmaceuticals, Inc. Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Oct 16
Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy Oct 09
Alnylam Highlights New Data from Helios-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 Oct 01
Alnylam Pharmaceuticals, Inc. Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress Aug 30
New minor risk - Shareholder dilution Aug 02
Alnylam Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2024 Aug 02
Second quarter 2024 earnings released: US$0.13 loss per share (vs US$2.21 loss in 2Q 2023) Aug 02
Alnylam Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 18
CEO & Director recently sold US$1.9m worth of stock Jun 27
Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations Jun 24
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024 May 03
First quarter 2024 earnings released: US$0.52 loss per share (vs US$1.40 loss in 1Q 2023) May 02
Alnylam Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 20
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension Apr 09
Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024 Mar 20
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives Mar 05
CEO & Director recently sold US$1.0m worth of stock Feb 21
Forecast to breakeven in 2026 Feb 20
Full year 2023 earnings released: US$3.53 loss per share (vs US$9.30 loss in FY 2022) Feb 16
Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024 Feb 15
Alnylam Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024 Jan 30
Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024 Jan 20
Forecast to breakeven in 2026 Dec 31
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk Nov 12
New minor risk - Shareholder dilution Nov 03
Third quarter 2023 earnings released: EPS: US$1.18 (vs US$3.32 loss in 3Q 2022) Nov 02 Alnylam Pharmaceuticals, Inc. Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
Alnylam Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
Alnylam Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis Oct 11
No longer forecast to breakeven Oct 10
Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc Sep 29 Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran Sep 08
No longer forecast to breakeven Aug 28 Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023
Second quarter 2023 earnings released: US$2.21 loss per share (vs US$2.30 loss in 2Q 2022) Aug 04
Alnylam Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
Alnylam Pharmaceuticals, Inc. Reports Updated Positive Interim Phase 1 Results for ALN-App, in Development for Alzheimer's Disease and Cerebral Amyloid Angiopathy Jul 18
Forecast to breakeven in 2025 May 26
Alnylam Pharmaceuticals, Inc. Presents 18-Month Results from the Apollo-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy May 21
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year of 2023 May 05
First quarter 2023 earnings released: US$1.40 loss per share (vs US$2.00 loss in 1Q 2022) May 05
CEO & Director recently sold US$1.5m worth of stock Apr 30
No longer forecast to breakeven Mar 21
Forecast to breakeven in 2025 Feb 25
Alnylam Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 03
Alnylam Pharmaceuticals, Inc. Announces Board Changes Jan 06
Alnylam Pharmaceuticals, Inc. Submits CTA Application for Aln-Khk, an Investigational RNAi therapeutic for the Treatment of Type 2 Diabetes Dec 22
Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration for ONPATTRO® (Patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis Dec 09
Alnylam Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022 Oct 28
Third quarter 2022 earnings released: US$3.32 loss per share (vs US$1.72 loss in 3Q 2021) Oct 27
Alnylam Pharmaceuticals, Inc. to Report Q3, 2022 Results on Oct 27, 2022 Oct 14
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 Oct 07
Alnylam Pharmaceuticals, Inc. Presents Additional Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy At Heart Failure Society of America Annual Meeting Oct 01
Alnylam Pharmaceuticals, Inc. Announces Executive Appointments Sep 22
Alnylam Pharmaceuticals, Inc. Receives Approval in Europe for AMVUTTRA (Vutrisiran) for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy Sep 21 Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals Announces Preliminary Phase 1 Data Supporting the Clinical Advancement of ALN-HSD Alnylam Presents Positive Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy Sep 08
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy Aug 30
Alnylam Appoints Elliott Sigal, M.D., Ph.D., to Board of Directors Aug 25
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Aug 04
Forecast to breakeven in 2024 Jul 29
Alnylam Pharmaceuticals, Inc. Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy Jul 23
Alnylam Pharmaceuticals, Inc. to Report Q2, 2022 Results on Jul 28, 2022 Jul 19
No longer forecast to breakeven Jun 16
Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults Jun 14
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of Iga Nephropathy Jun 10
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering Rna to the Central Nervous System and Other Extrahepatic Tissues Jun 03 Alnylam Pharmaceuticals, Inc. Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 May 25
Alnylam Pharmaceuticals, Inc. Announces New Positive Results from an 18-Month Analysis of Exploratory Cardiac Endpoints in the HELIOS-A Phase 3 Study of Vutrisiran May 24
Alnylam Pharmaceuticals, Inc. Announces That Health Canada Has Issued A Notice of Compliance (Noc) Authorizing Oxlumo™ (Lumasiran) Injection for Subcutaneous Use for the Treatment May 19
First quarter 2022 earnings released: US$2.00 loss per share (vs US$1.71 loss in 1Q 2021) Apr 29
Alnylam Pharmaceuticals, Inc. to Report Q1, 2022 Results on Apr 28, 2022 Apr 15 Alnylam Pharmaceuticals, Inc. Announces Retirement of Steven Paul from Board of Directors
Alnylam Pharmaceuticals, Inc. Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran Apr 05
Alnylam Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1 Mar 03
Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022 Feb 11
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 11
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy Jan 22 Shareholder Returns 0HD2 GB Biotechs GB Market 7D -0.3% -4.2% -2.6% 1Y 28.2% -24.5% 2.4%
See full shareholder returns
Return vs Industry: 0HD2 exceeded the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: 0HD2 exceeded the UK Market which returned 2.4% over the past year.
Price Volatility Is 0HD2's price volatile compared to industry and market? 0HD2 volatility 0HD2 Average Weekly Movement 4.8% Biotechs Industry Average Movement 6.9% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0HD2 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0HD2's weekly volatility (5%) has been stable over the past year.
About the Company Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.
Show more Alnylam Pharmaceuticals, Inc. Fundamentals Summary How do Alnylam Pharmaceuticals's earnings and revenue compare to its market cap? 0HD2 fundamental statistics Market cap US$31.66b Earnings (TTM ) -US$332.26m Revenue (TTM ) US$2.09b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0HD2 income statement (TTM ) Revenue US$2.09b Cost of Revenue US$306.41m Gross Profit US$1.79b Other Expenses US$2.12b Earnings -US$332.26m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.58 Gross Margin 85.37% Net Profit Margin -15.86% Debt/Equity Ratio 7,566.4%
How did 0HD2 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 13:44 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Alnylam Pharmaceuticals, Inc. is covered by 66 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research Huidong Wang Barclays Emily Bodnar Berenberg
Show 63 more analysts 